Macrogenics (MGNX) Tax Provisions (2024 - 2025)
Macrogenics' (MGNX) quarterly Tax Provisions came in at -$805000.0 in Q4 2025, down 185.28% year-on-year from $944000.0 in Q4 2024, and down 866.67% on a QoQ basis from $105000.0 in Q2 2025.
Macrogenics (MGNX) Tax Provisions (2024 - 2025) Analysis & Trends
Macrogenics (MGNX) has 2 years of Tax Provisions data on file, last reported at -$805000.0 in Q4 2025.
- On a quarterly basis, Tax Provisions fell 185.28% year-over-year to -$805000.0 in Q4 2025; TTM through Dec 2025 was $244000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$700000.0, down 174.15% from the prior year.
- Tax Provisions for Q4 2025 stood at -$805000.0, down from $105000.0 in the prior quarter.
- Over the last five years, Tax Provisions for MGNX reached as high as $944000.0 in Q4 2024 and fell as low as -$805000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 31.86 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -805,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Dec 31, 2024 | 944,000.00 |